

Notice of correction

In the November 1998 issue of the Journal, in the article by Alderman and associates titled "Analysis of Coronary Graft Patency After Aprotinin Use: Results From the International Multicenter Aprotinin Graft Patency Experience (IMAGE) Trial" (1998;116:716-30), an error was made. In Table I, the heading "Angiography performed" should extend over three subheadings: "All sites," US sites," and "Danish and Israeli sites." The corrected table is given below.

Table I. Characteristics of all patients and those included in the assessment of the saphenous vein grafts

	Saphenous vein graft performed					
	All study patients		Angiography not performed	Angiography performed		
	Aprotinin	Placebo		All sites	US sites	Danish and Israeli sites
Patient No.	436	434	134	703*	381	322
Preop ASA/NSAID (%)	50.1	50.0	53.0	49.4	62.2	34.2
Clinical features						
Age (yr, mean \pm SD)	61.8 \pm 9.1	62.3 \pm 9.1	64.3 \pm 9.7†	61.8 \pm 9.0†	61.6 \pm 9.4	62.0 \pm 8.6
Male (%)	87.4	86.9	85.1	88.3	90.6	85.7
Weight (kg, mean \pm SD)	81.7 \pm 14.1	83.3 \pm 15.0	82.3 \pm 14.9	82.5 \pm 14.4	85.9 \pm 15.0	78.5 \pm 12.5‡
BSA (m, mean \pm SD)	1.94 \pm 1.8	1.96 \pm 2.0	1.95 \pm 2.0	1.95 \pm 1.9	2.00 \pm 1.9	1.89 \pm 1.7‡
NYHA class III-IV (%)	62.2	64.5	68.7	62.7	73.8	49.7‡
MI \leq 30 d preop (%)	11.7	14.3	16.4	12.7	19.2	4.97‡
LVEF \leq 0.5 (%)	29.2	26.3	25.6	28.8	28.1	29.6
Adjunctive drugs						
ASA within 2 days of operation (%)	35.3	37.3	41.8	35.1	42.8	26.1‡
Total protamine (mg, mean \pm SD)	338 \pm 115	337 \pm 10.5	310 \pm 115†	341 \pm 109†	369 \pm 105	309 \pm 104‡
Total heparin (U, mean \pm SD)	59,200 \pm 17,537	59,627 \pm 15,571	59,567 \pm 20,196	59,410 \pm 16,002	56,560 \pm 14,517	62,782 \pm 17,015‡
Laboratory analyses						
Preop PTT (s, mean \pm SD)	31.6 \pm 14.3	32.4 \pm 16.6	34.0 \pm 22.0	31.7 \pm 14.0	36.1 \pm 16.2	26.4 \pm 8.2
Preop Hgb (g/dL, mean \pm SD)	13.98 \pm 1.2	13.97 \pm 1.3	13.72 \pm 1.4†	14.03 \pm 1.3†	14.04 \pm 1.4	14.01 \pm 1.3
Preop creatinine (mg/dL, mean \pm SD)	1.13 \pm 0.23	1.3 \pm 0.21	1.15 \pm 0.24	1.13 \pm 0.22	1.11 \pm 0.24	1.15 \pm 0.19
Graft insertions (by patient)						
Total/patient (mean \pm SD)	3.03 \pm 0.81	3.03 \pm 0.85	3.16 \pm 0.76	3.08 \pm 0.79	3.08 \pm 0.74	3.07 \pm 0.84
SVG/patient (mean \pm SD)	2.06 \pm 0.83	2.08 \pm 0.87	2.19 \pm 0.76	2.14 \pm 0.76	2.15 \pm 0.80	2.11 \pm 0.75
Y or sequential SVG (%)	24.1	22.7	26.1	23.9	31.2	15.2‡
ITA graft (%)	89.4	89.6	91.1	88.9	86.1	92.2
Total graft insertions (No.)	1474	1454	321	1734	990	744
Distal vessel \leq 1.5 mm (% of grafts)	54.1	51.8	59.4	56.5	54.3	59.4
Distal vessel quality:						
Good (% of grafts)	46.0	46.4	44.7	45.6	56.5	31.3‡
Fair/poor (% of grafts)	54.0	53.6	55.3	54.4	43.5	68.7‡
Graft size:						
Large (% of grafts)	12.6	14.0	16.7	14.8	11.8	18.7‡
Normal/small (% of grafts)	87.4	86.0	83.3	85.2	88.2	81.3‡

SVG, Saphenous vein graft; NSAID, nonsteroidal anti-inflammatory drug; ASA, acetylsalicylic acid (aspirin); BSA, body surface area; LVEF, left ventricular ejection fraction; PTT, partial thromboplastin time; Hgb, hemoglobin.

*Thirty patients underwent angiography, but had no vein grafts.

† $P < .01$ when comparing angiography and no-angiography groups.

‡ $P < .01$ when comparing US and European sites.